Risk of kidney failure and death associated with target-dose (vs. below-target-dose) RAS inhibitors in HFrEF, HFmrEF and HFpEF: Spline-based reassessment of subgroup findings

By afschroeder • February 23, 2026

Raman VK, Vargas JD, Moore HJ, Wu WC, Patel SS, Zhang S, Morgan CJ, Lam PH, Heidenreich PA, Lu F, Ahmed AA, Fonarow GC, Ahmed A. Risk of kidney failure and death associated with target-dose (vs. below-target-dose) RAS inhibitors in HFrEF, HFmrEF and HFpEF: Spline-based reassessment of subgroup findings. Am J Med. 2026 Feb 21:S0002-9343(26)00079-3. doi: 10.1016/j.amjmed.2026.01.035. Epub ahead of print. PMID: 41724615.

Tags: Cardiology/Epi, Publications

Maternal hyperglycemia disrupts cardiomyocyte maturation via aberrant nucleotide metabolism and suppression of AMPK signaling

Nakano H, Kawahira N, Vesprey A, Nakano A. Maternal hyperglycemia disrupts cardiomyocyte maturation via aberrant nucleotide metabolism and suppression of AMPK signaling. Cell Rep. 2026[...]

Variation in Vasoactive Treatment Selection for Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network (CCCTN)

Hamilton DE, Shriver JL, Patel SM, Park JG, Michos ZE, Mathis MR, Adie SK, Alviar CL, Barnett CF, Berg DD, Bennett CE, Bohula EA, Carnicelli[...]

National Evaluation of Racial, Ethnic, and Insurance-Based Disparities in Interhospital Transfer of Patients With Ischemic Stroke

Turner AC, Li S, Wahab F, Zhao J, Thomas K, Poudel R, Reeves M, Smith EE, Messé SR, Fonarow GC, Schwamm LH, Zachrison KS. National[...]